GlassScriptPhysician profile
Hani I Salib
NPI 1629065925
$3,497.74
in general payments reported to CMS, 2019-2025
20 companies · $601 in 2025
The $601 reported for 2025 was more than what 77% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $609 · 2020: $268 · 2021: $354 · 2022: $407 · 2023: $431 · 2024: $827 · 2025: $601.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,860.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,859.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,415.33 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Abbott Laboratories | $426.63 | 2021-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Novo Nordisk INC | $342.63 | 2019-2025 | Rybelsus, Ozempic |
| Boehringer Ingelheim Pharmaceuticals, INC. | $266.03 | 2019-2024 | Jardiance, Spiriva Respimat, Stiolto Respimat |
| Bayer Healthcare Pharmaceuticals INC. | $168.22 | 2023-2024 | |
| Glaxosmithkline, LLC. | $152.27 | 2019-2025 | Trelegy Ellipta, Arexvy |
| Edwards Lifesciences Corporation | $150.02 | 2021 | |
| Abbvie INC. | $146.99 | 2022-2023 | Synthroid |
| Sanofi-Aventis U.S. LLC | $108.85 | 2019-2025 | |
| Amgen INC. | $92.06 | 2019-2024 | Evenity, Prolia, Repatha |
| Allergan, INC. | $40.30 | 2019 | |
| Dexcom, INC. | $31.50 | 2021 | |
| Boston Scientific Corporation | $29.21 | 2023 | Watchman |
| Philips North America LLC | $25.03 | 2023 | |
| Amarin Pharma, INC. | $19.90 | 2020 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $18.11 | 2019 | |
| Lilly USA, LLC | $17.57 | 2022 | |
| Pfizer INC. | $16.93 | 2023 | |
| Astellas Pharma US INC | $15.77 | 2020 | |
| Gilead Sciences, INC. | $14.39 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hani Salib listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.